Accelerating Discovery Through a Better Platform

Metabolic diseases like diabetes, high blood pressure and high cholesterol impact about half of the U.S. adult population and create a tremendous cost in terms of quality of life of the patients, expenses to the healthcare system, and lost productivity to society. They also all stem from similar root causes: patient choices around diet, exercise, smoking and other lifestyle factors. Because they have similar causes, similar solutions are needed to change these behaviors and address the root causes of the diseases.

That insight is the foundation for the Better Therapeutics R&D Platform. Over the past five years, we have developed a prescription digital therapeutic (PDT) product to treat the underlying causes of diabetes. With the input of experts in behavioral therapy, lifestyle medicine, AI, and software design and development, our PDT for diabetes has been shown in pilot clinical trials to reduce the blood sugar levels in diabetes patients with efficacy similar to leading prescription drugs.

Since the same fundamental behaviors that cause diabetes also cause other cardiometabolic diseases, everything that we learned in the creation of our Better Therapeutics’ PDT for diabetes also applies to these other diseases. As a result, we have also demonstrated efficacy of a PDT for high blood pressure using similar principles. The approach greatly reduces the cost and time required for the development of PDT’s for new indications.

In parallel with the pivotal trial the company is conducting in diabetes in 2021, we will be conducting pilot trials in hypertension, hyperlipidemia, and hypertriglyceridemia. With positive data, we will then move directly into pivotal trials in those diseases, and seek FDA 510k clearance thereafter. Given that there are another 20+ diseases with similar root causes, Better Therapeutics believes that it is possible to build a portfolio of PDT’s in cardiometabolic diseases that efficiently build from the same R&D platform.